Business
GCANRx Announces Uplisting to New Market Tier
GCANRx Announces Uplisting to New Market Tier.
About this update from Greater Cannabis Co Inc.
[{"type":"text","content":"\r\n\r\n \r\n \r\n GCANRx Announces Uplisting to New Market Tier\r\n \r\n \r\n\r\n\r\nGCANRx Announces Uplisting to New Market Tier\r\n\r\n\r\n\r\n\r\n\r\nBALTIMORE, June 30, 2025 (GLOBE NEWSWIRE) -- Greater Cannabis Company, Inc. (“GCANRx” or the “Company”) (OTC: GCAN) a biopharmaceutical company pioneering development of next generation cannabinoid therapeutics and consumer products is pleased to announce that its application to the OTCID Basic Market has been officially approved by OTC Markets Group. The upgrade will take effect upon the market's launch on July 1, 2025 and marks a significant milestone in GCAN’s ongoing efforts to strengthen its presence in the capital markets. The Company's transition to the OTCID Basic Market represents a higher standard for transparency and compliance, increased visibility and credibility with investors. To qualify for this market, companies must meet high financial standards, follow best practice corporate governance, demonstrate compliance with U.S. securities laws and be current in their disclosure. \"We are excited to advance our capital markets strategy with this uplist to OTCID. Acceptance into the OTCID Basic Market validates our commitment to regulatory discipline and positions us for greater visibility and access to GCAN’s shares in a more structured and enhanced trading environment,\" said Aitan Zacharin, GCAN’s Chief Executive Officer. “We anticipate that trading on the OTCID will not only help in increasing our shareholder base, but will also increase liquidity and transparency for our shareholders through a respected platform.” ENDS For GCANRx Investor Relations inquiries visit www.gcanrx.com, or contact [email protected]. To receive the latest information about GCANRx sign up to the investor email at https://bit.ly/2ZNlBoj or follow @GCANRX on Twitter. About Greater Cannabis Company: The Greater Cannabis Company (OTC: GCAN), (“GCANRx” or the “Company”) is a publicly traded clinical stage biopharmaceutical company focused on the development of new and effective cannabinoid therapeutics. The Company conducts medical research, and is pursuing clinical trials, to develop innovative cannabis-based treatments for various medical conditions and their symptoms with an initial focus on neurop...